AKT1 and central nervous system cancer: As mTORC2 knockdown suppresses the induction of glycolysis in response to PI3K and Akt inhibitors, it has been proposed that their combination with dual mTORC1/2 inhibitors will promote glioma cell death and tumor regression (Masui et al., 2013).